Use of an abnormal laboratory value-drug combination alert to detect drug-induced thrombocytopenia in critically Ill patients

Journal of Critical Care

Volumn 27, Issue 3, 2012, Pages 242-249

  Harinstein, Lisa M ^a   Kane Gill, Sandra L ^b   Smithburger, Pamela L ^b,c   Culley, Colleen M ^b,c   Reddy, Vivek K ^c,d   Seybert, Amy L ^b,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Universigy of Pittsburgh   (United States)

Author keywords

Adverse drug reaction; Computerized decision support system; Critically ill; Thrombocytopenia

Indexed keywords

ACETYLSALICYLIC ACID; CEFEPIME; FAMOTIDINE; GLYCERYL TRINITRATE; HEPARIN; MEROPENEM; PARACETAMOL; PIPERACILLIN; SIMVASTATIN; TAZOBACTAM; VANCOMYCIN;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DECISION SUPPORT SYSTEM; DRUG INDUCED DISEASE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PREDICTIVE VALUE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; CAUSALITY; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEDICAL ORDER ENTRY SYSTEMS; MEDICATION SYSTEMS, HOSPITAL; MIDDLE AGED; PENNSYLVANIA; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; THROMBOCYTOPENIA;

EID: 84861192027     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.02.014     Document Type: Article

References (45)

1. Strauss R., Wehler M., Mehler K., et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002, 30:1765-1771.
2. Crowther M.A., Cook D.J., Meade M.O., et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005, 20:348-353.
3. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356:1255-1259.
4. Osheroff J.A., Teich J.M., Middleton B., et al. A roadmap for national action on clinical decision support. J Am Med Inform Assoc 2007, 14:141-145.
5. Handler S.M., Altman R.L., Perera S., et al. A systematic review of the performance characteristics of clinical event monitor signals used to detect adverse drug events in the hospital setting. J Am Med Inform Assoc 2007, 14:451-458.
6. Azaz-Livshits T., Levy M., Sadan B., et al. Computerized surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998, 45:309-314.
7. Pestotnik S.L. Expert clinical decision support systems to enhance antimicrobial stewardship programs: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2005, 25:1116-1125.
8. Hripcsak G., Clayton P.D., Jenders R.A., et al. Design of a clinical event monitor. Comput Biomed Res 1996, 29:194-221.
9. Dormann H., Criegee-Rieck M., Neubert A., et al. Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology. Aliment Pharmacol Ther 2004, 19:303-309.
10. Kaboli P.J., Glasgow J.M., Jaipaul C.K., et al. Identifying medication misadventures: poor agreement among medical record, physician, nurse, and patient reports. Pharmacotherapy 2010, 30:529-538.
11. Moore C., Li J., Hung C., et al. Predictive value of alert triggers for identification of developing adverse drug events. J Patient Saf 2009, 5:223-228.
12. Raschke R.A., Gollihare B., Wunderlich T.A., et al. A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. JAMA 1998, 280:1317-1320.
13. Thuermann P.A., Windecker R., Steffen J., et al. Detection of adverse drug reactions in a neurological department: comparison between intensified surveillance and a computer-assisted approach. Drug Saf 2002, 25:713-724.
14. Kane-Gill S.L., Dasta J.F., Schneider P.J., et al. Monitoring abnormal laboratory values as antecedents to drug-induced injury. J Trauma 2005, 59:1457-1462.
15. Cullen D.J., Bates D.W., Small S.D., et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv 1995, 21:541-548.
16. Cullen D.J., Sweitzer B.J., Bates D.W., et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 1997, 25:1289-1297.
17. Kane-Gill S.L., Bellamy C.J., Verrico M.M., et al. Evaluating the positive predictive values of antidote signals to detect potential adverse drug reactions (ADRs) in the medical intensive care unit (ICU). Pharmacoepidemiol Drug Saf 2009, 18:1185-1191.
18. Katsaragakis S., Papadimitropoulos K., Antonakis P., et al. Comparison of Acute Physiology and Chronic Health Evaluation II (APACHE II) and Simplified Acute Physiology Score II (SAPS II) scoring systems in a single Greek intensive care unit. Crit Care Med 2000, 28:426-432.
19. Brinkman S, Bakhshi-Raiez F, Abu-Hanna A, et al. External validation of acute physiology and chronic health evaluation IV in Dutch intensive care units and comparison with Acute Physiology and Chronic Health Evaluation II and Simplified Acute Physiology Score II. J Crit Care 26.
20. TheraDoc® Web site Accessed December 7, 2010. http://www.theradoc.com.
21. George J.N., Raskob G.E., Shah S.R., et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998, 129:886-890.
22. Kramer M.S., Leventhal J.M., Hutchinson T.A., et al. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979, 242:623-632.
23. Jones J.K. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Community Health 1982, 5:58-67.
24. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
25. Kane-Gill S.L., Visweswaran S., Saul M.I., et al. Computerized detection of adverse drug reactions in the medical ICU. Int J Med Inform 2011, 80:570-578.
26. Oderda G.M., Said Q., Evans R.S., et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother 2007, 41:400-407.
27. Dormann H., Muth-Selbach U., Krebs S., et al. Incidence and costs of adverse reactions during hospitalization. Drug Saf 2000, 22:161-168.
28. Evans R.S., Pestotnik S.L., Classen D.C., et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994, 28:523-527.
29. Kilbridge P.M., Campbell U.C., Cozart H.B., et al. Automated surveillance for adverse drug events a community hospital and an academic medical center. J Am Med Inform Assoc 2006, 13:372-377.
30. Visentin G.P., Liu C.Y. Drug-induced thrombocytopenias. Hematol Oncol Clin North Am 2007, 21:685-696.
31. Priziola J.L., Smythe M.A., Dager W.E. Drug-induced thrombocytopenia in critically ill patients. Crit Care Med 2010, 38:S145-S154.
32. Agency for Healthcare Research and Quality Triggers and targeted injury detection systems Accessed February 23, 2010. http://www.ahrq.gov/qual/triggers/.
33. Agbabiaka T.B., Savovic J., Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 2008, 31:21-37.
34. Kane-Gill S.L., Kirisci L., Pathak D.S. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit?. Ann Pharmacother 2005, 39:1823-1827.
35. Levy M., Azaz-Livshits T., Sadan B., et al. Computerized surveillance of adverse drug reactions in hospital: implementation. Eur J Clin Pharmacol 1999, 54:887-892.
36. Murff H.J., Patel V.L., Hripcsak G., et al. Detecting adverse events for patient safety research: a review of current methodologies. J Biomed Inform 2003, 36:131-143.
37. Morimoto T., Gandhi T.K., Seger A.C., et al. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004, 13:306-314.
38. Bates D.W., Evans R.S., Murff H., et al. Detecting adverse events using information technology. J Am Med Inform Assoc 2003, 10:115-128.
39. Tegeder I., Levy M., Muth-Selbach U., et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999, 47:557-564.
40. Evans R.S., Pestotnik S.L., Classen D.C., et al. Prevention of adverse drug events through computerized surveillance. Proceedings-the Annual Symposium on Computer Applications in Medical Care 1992, 437-441.
41. Jha A.K., Laguette J., Seger A., et al. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Inform Assoc 2008, 15:647-653.
42. Reducing and preventing adverse drug events to decrease hospital costs 2001, Agency for Healthcare Research and Quality, Rockville (Md), AHRQ Publication Number 01-0020.
43. Silverman J.B., Stapinski C.D., Huber C., et al. Computer-based system for preventing adverse drug events. Am J Health Syst Pharm 2004, 61:1599-1603.
44. Peterson J.F., Williams D.H., Seger A., et al. Drug-lab triggers have the potential to prevent adverse drug events in outpatients. J Am Med Inform Assoc 2002, 9:S39-40.
45. Hartis C.E., Gum M.O., Lederer J.W. Use of specific indicators to detect warfarin-related adverse events. Am J Health Syst Pharm 2005, 62:1683-1688.